Saturday November 21 2009 | Biotechnology feed | All feeds
|
|
|
News Articles on PDL BioPharma, Inc.PDL BioPharma Announces Special Dividend PaymentINCLINE VILLAGE, Nev., Nov. 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay a $2 PDL BioPharma Announces Closing of $300,000,000 Securitization TransactionINCLINE VILLAGE, Nev., Nov. 2 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it closed on its prev PDL BioPharma Announces Pricing of $300,000,000 Securitization TransactionINCLINE VILLAGE, Nev., Oct. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has priced a $300 PDL BioPharma Announces Third Quarter 2009 Financial Results-- The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.http://www.bioportfolio.com/news/PDL-BioPharma-Announces-Third-Quarter-2009.html - Wednesday October 28 2009 PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, PDL BioPharma Reschedules Third Quarter 2009 Financial Results Conference Call for 8:30 a.m. ET on October 28, 2009INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hol PDL BioPharma Completes October 1 Special Dividend PaymentINCLINE VILLAGE, Nev., Oct. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced th PDL BioPharma Announces Second Quarter 2009 Financial Results-- The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.http://www.bioportfolio.com/news/PDL_BioPharma_Announces_Second_Quarter_2009.html - Thursday July 30 2009 PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughl PDL BioPharma Announces Record Date for October 1 Dividend PaymentINCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that all shareholders owning shar PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
INCLINE VILLAGE, Nev., June 8 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue PDL BioPharma to Present at the 8th Annual JMP Securities Research Conference on May 18, 2009INCLINE VILLAGE, Nev., May 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the compa PDL BioPharma Announces First Quarter 2009 Financial Results- Revenues From Continuing Operations Increase 25 Percent to - Conference Call Today at 4:30 p.m. Eas PDL BioPharma To Announce First Quarter 2009 Financial Results and Hold Conference Call May 7, 2009INCLINE VILLAGE, Nev., April 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold a con PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer- Company Updates Board of Directors Audit Committee Members and Complies with Nasdaq Rule - INCLINE VILLAGE, Nev., April 2 Alexion Pharmaceuticals and PDL BioPharma Resolve Patent DisputeAlexion Licenses PDL's Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNews |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
